The Sales & Marketing Effectiveness in Chemicals Forum will bring together industry leaders as well as experts responsible and deeply involved in sales and marketing strategies.
Portfolio prioritization tactics in a smaller-sized organization
Read the full interview with Corky LaVallee from Dynavax Technologies, and learn more about portfolio management and project prioritization strategies.
1. What is the main difference in portfolio management and prioritization between big companies and smaller-sized organizations?
The most obvious difference is that in big companies the portfolios are so large that no one person can get their arms around the potential opportunities and trade-offs between costs, ROIs and risks in the various options available for investing. In addition, there is usually intense competition for resources between the various assets.
2. How to be sure that the right projects are being performed? What are the key steps for successful prioritization?
"Right" is relative to the company's situation and objectives. The bottom line is that every company has finite resources, usually less than the ways they can invest those resources. If you can advance every compound you have, you generally will; if not, you want to invest your constrained resources in a way that maximizes your potential return. To do that, you need to estimate the costs associated with moving the compound forward, the probability of success for each step (or risk of failure), and the overall value of that asset, which is influenced by things like unmet medical need, size of the market, the competition, etc.
3. What are the main pitfalls that can occur in the process of prioritization?
I've already touched on some of them. Other risks are imprecision of methodology, differences in effectiveness of communication between teams, personal biases of the management team members, and going through a rigorous prioritization process and then doing everything any how.
Interested in this topic?
Advanced Protein Aggregation & Characterization
This training will focus on occurrence of particles in drug products, effects of protein aggregates, critical process and parameters. Attendees will gain overview of on utility and limits of predictive experiments, learn concerns from the authorities and relevant aggregation guidelines, and more.
CMC Analytical Comparability: Methods & Strategies for Biologics, Biosimilars & Biobetters
Attendees will be introduced to comparability in biosimilar development, the analytical strategies of protein characterization of biosimilars, the structure of proteins, in vitro pharmacology and much more.
Corporate Compliance & Transparency in the Pharmaceutical Industry
This two-day conference will serve as a platform for an open and dynamic dialogue with HCPs and patients to achieve common goals. Learn how to embed compliance in the business and develop one simple system for managing compliance & transparency in a complex and regulated environment.
Turning Patient Feedback to Meaningful Resource for Care Delivery
Read the interview with Nasser Al Naimi, Deputy Chief Quality Officer at Hamad Medical Corporation, and Co-Director at Hamad Healthcare Quality Institute, and learn how to turn your data into strategic information to drive patient-family centered care.
Creating & Leading Patient Experience Excellence
Read the full interview with Dr. Ahmed Mohammad Abu-Abah, CEO at King Abdullah BinAbdulaziz University Hospital and gain insight into the creating & leading patient experience excellence.
Excelling in PV is not only about Technical Expertise
For a PV leader, to be successful can look like a daily Herculean work: meeting a crucial mandate to minimize harm to patients, while ensuring that a product is prescribed to the right population, and maintaining the highest level of compliance within a very complex set of worldwide regulations.